Novavax COVID-19 Vaccine Trial

Project summary:

A phase 3, randomised, observer-blinded, placebo-controlled trial to evaluate the efficacy and safety of a Sars-Cov-2 recombinant spike protein nanoparticle vaccine (Sars-Cov-2 RS) with Matrix-M1TN adjuvant in adult participants 18-84 years of age in the United Kingdom.

Lead institution:

St George's Vaccine Institute

Vaccine type: